137 related articles for article (PubMed ID: 37844755)
21. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Dong B; Singh AB; Fung C; Kan K; Liu J
Atherosclerosis; 2014 Aug; 235(2):449-62. PubMed ID: 24950000
[TBL] [Abstract][Full Text] [Related]
22. High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
Dong B; Singh AB; Azhar S; Seidah NG; Liu J
Atherosclerosis; 2015 Apr; 239(2):364-74. PubMed ID: 25682035
[TBL] [Abstract][Full Text] [Related]
23. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors.
Persson L; Gälman C; Angelin B; Rudling M
Endocrinology; 2009 Mar; 150(3):1140-6. PubMed ID: 19008317
[TBL] [Abstract][Full Text] [Related]
24. Irisin inhibits PCSK9 expression through activating AMPK-SREBP2 pathway.
Xu R; Liu Q; Ma X; Hou J
Biochem Biophys Res Commun; 2022 Nov; 630():77-83. PubMed ID: 36152348
[TBL] [Abstract][Full Text] [Related]
25. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
26. Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells.
Choi HK; Hwang JT; Nam TG; Kim SH; Min DK; Park SW; Chung MY
Food Funct; 2017 Dec; 8(12):4582-4591. PubMed ID: 29130084
[TBL] [Abstract][Full Text] [Related]
27. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.
Xu RX; Liu J; Li XL; Li S; Zhang Y; Jia YJ; Sun J; Li JJ
J Transl Med; 2015 Mar; 13():87. PubMed ID: 25889684
[TBL] [Abstract][Full Text] [Related]
28. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
29. Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a.
Cui CJ; Jin JL; Guo LN; Sun J; Wu NQ; Guo YL; Liu G; Dong Q; Li JJ
J Transl Med; 2020 May; 18(1):195. PubMed ID: 32398139
[TBL] [Abstract][Full Text] [Related]
30. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
31. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
[TBL] [Abstract][Full Text] [Related]
32. Contribution of high-fat diet-induced PCSK9 upregulation to a mouse model of PCOS is mediated partly by SREBP2.
Guo WJ; Wang YC; Ma YD; Cui ZH; Zhang LX; Nie L; Zhang XQ; Wang MJ; Zhang JH; Yuan DZ; Yue LM
Reproduction; 2021 Oct; 162(6):397-410. PubMed ID: 34554110
[TBL] [Abstract][Full Text] [Related]
33. Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.
Jia YJ; Zhang Y; Liu J; Guo YL; Xu RX; Li JJ
Chin J Integr Med; 2016 Feb; 22(2):96-100. PubMed ID: 24993334
[TBL] [Abstract][Full Text] [Related]
34. Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression.
Wang J; Wang YS; Huang YP; Jiang CH; Gao M; Zheng X; Yin ZQ; Zhang J
Phytomedicine; 2021 Oct; 91():153688. PubMed ID: 34380071
[TBL] [Abstract][Full Text] [Related]
35. Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells.
Ali A; Unnikannan H; Shafarin J; Bajbouj K; Taneera J; Muhammad JS; Hasan H; Salehi A; Awadallah S; Hamad M
Endocrine; 2022 Jun; 76(3):543-557. PubMed ID: 35237909
[TBL] [Abstract][Full Text] [Related]
36. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
37. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
38. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
Dong B; Singh AB; Shende VR; Liu J
Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.
Sucajtys-Szulc E; Szolkiewicz M; Swierczynski J; Rutkowski B
Mol Cell Biochem; 2016 Jan; 411(1-2):281-7. PubMed ID: 26481479
[TBL] [Abstract][Full Text] [Related]
40. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]